Abzena PLC Termination of licence agreement (1930K)
09 April 2018 - 5:25PM
UK Regulatory
TIDMABZA
RNS Number : 1930K
Abzena PLC
09 April 2018
Abzena plc
Termination of licence agreement
Cambridge, UK, 9 April 2018 - Abzena plc (AIM: ABZA, 'Abzena',
the 'Company' or the 'Group'), a life sciences group providing
services and technologies enabling the development and manufacture
of biopharmaceutical products, has received notice from Halozyme
Therapeutics, Inc ('Halozyme'), of the termination of the
Collaboration and Licence Agreement relating to Halozyme's use of
the Group's ThioBridge linker technology for the development of
antibody drug conjugate products.
Under the Agreement, Halozyme had progressed the development of
HTI-1511, an anti-EGFR antibody drug conjugate product. Preclinical
results from this program were presented at the 2017 meeting of the
American Association for Cancer Research reporting the significant
activity of HTI-1511 against multiple tumour types and a safety
profile suitable for candidate nomination.
-Ends-
Enquiries:
Abzena plc
John Burt, Chief Executive
Officer
Julian Smith, Chief Financial
Officer +44 1223 903498
Numis (Nominated Adviser and
Broker)
Clare Terlouw / James Black
/ Paul Gillam +44 20 7260 1000
N+1 Singer (Joint Broker)
Aubrey Powell / Liz Yong +44 20 7496 3000
Instinctif Partners +44 20 7457 2020
Melanie Toyne Sewell / Alex abzena@instinctif.com
Shaw
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products.
The term 'Abzena inside' is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on 'Abzena inside' products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA):
-- Immunology research studies, including immunogenicity
assessment of candidate biopharmaceutical products;
-- Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
-- Cell line development for the manufacture of recombinant proteins and antibodies;
-- Contract process development and GMP manufacture of
biopharmaceuticals, including monoclonal antibodies and recombinant
proteins for preclinical and clinical studies;
-- Contract synthetic chemistry and bioconjugation research
services, focused on antibody-drug conjugates (ADCs);
-- Proprietary site-specific conjugation technologies and novel
payloads for ADC development; and
-- GMP manufacturer of ADC linkers, payloads & combined linker-payloads.
For more information, please see www.abzena.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRFKFDBKBKBCQK
(END) Dow Jones Newswires
April 09, 2018 03:25 ET (07:25 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024